EssilorLuxottica SA (ESLOY) AI Stock Analysis

• Market Cap: $115.20B
• Dividend Yield: 1.41%
• Average Volume (3M): 2.59K
• Price to Earnings (P/E): 55.7
• Beta (1Y): 0.73
• Revenue Growth: 6.06%
• EPS Growth: 3.53%
• Country: US
• Employees: 153,498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.73
• Shares Outstanding: 926,579,160
• 10 Day Avg. Volume: 2,986
• 30 Day Avg. Volume: 2,591
• PEG Ratio: -8.27
• Price to Book (P/B): 3.18
• Price to Sales (P/S): 4.52
• P/FCF Ratio: 34.22
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 4.05
• Enterprise Value/Gross Profit: 6.75
• Enterprise Value/Ebitda: 19.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 4.45
• Revenue Forecast (FY): $36.96B

• Rating: 67 Neutral
• Price Target: $166.00 ▲(4.36% Upside)
• Action: Downgraded Date: 02/18/26
• Date: Action: Downgraded 02/18/26

The score is driven primarily by solid underlying financial performance (strong growth and resilient cash generation) and a supportive earnings outlook, partially offset by rising leverage and near-term margin pressure. Technicals are soft with negative momentum and price below key moving averages, and valuation is stretched given the high P/E with only a modest dividend yield.

Positive Factors

Sustained revenue growth

Multi-year top-line expansion and broad regional acceleration indicate durable end-market demand for lenses and branded eyewear. Consistent revenue growth supports scale benefits, stronger negotiating leverage with suppliers, and the ability to fund strategic R&D and retail investments over the medium term.

Strong cash generation

High and improving cash flow provides lasting financial flexibility to fund R&D, capex for wearables/Med‑Tech, and M&A without overreliance on equity issuance. Even with moderate cash conversion, persistent positive free cash flow supports investment cycles and de-risks execution on long-term initiatives.

Brand, product & med‑tech leadership

Leading global brands, rapid AI wearables adoption and FDA‑authorized myopia products create structural competitive advantages. These assets deepen customer relationships, enable premium pricing and recurring clinical services, and position the company to capture long-term market share in both consumer and medical segments.

Negative Factors

Rising leverage

Meaningful debt increase reduces balance sheet flexibility and raises sensitivity to higher interest rates. Sustained leverage at elevated levels can restrict capital allocation choices, increase financing costs over time, and heighten downside risk if revenue or margin recovery is slower than planned.

Gross margin compression

Rapid growth in lower‑margin AI wearables and one‑time tariffs materially compressed gross margins. If the high‑growth product mix or trade costs persist before scale or price recovery, operating profitability will remain pressured and margin normalization may take several quarters to years.

Persistent FX, tariff & financing headwinds

Combined tariff, currency and rising financing costs create structural earnings volatility. These macro and policy-driven headwinds can erode operating leverage and cash flow predictability, forcing more conservative investment pacing and compressing medium‑term net margin recovery.

EssilorLuxottica SA Business Overview & Revenue Model

Company Description

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions; and Transitions Signature Gen 8 photochromic lens, as well as develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses and Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, and SolarShield brands; Reebok, Steve Madden, Betsey Johnson, Nine West, Dockers, French Connection, Ironman, Rawlings, Bodyglove, Panama Jack, Marvel, and Disney; Bolon, Molsion, Qina, and Prosun brands; and Mujosh and Aojo brands. It has a network of 490 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

How the Company Makes Money

EssilorLuxottica generates revenue through several key streams. The largest portion comes from the sale of ophthalmic lenses, which are essential for vision correction and come in various types, including single vision, bifocal, and progressive lenses. The company also generates significant income from its eyewear segment, which includes both prescription glasses and sunglasses. Additionally, EssilorLuxottica benefits from its extensive retail network, which includes brands like Sunglass Hut and Optical shops, where it sells its products directly to consumers. The company has established numerous partnerships with both eyewear retailers and eye care professionals, enhancing its distribution capabilities. Moreover, ongoing investments in technology and innovation, such as digital dispensing solutions and smart eyewear, contribute to its growth and revenue diversification.

EssilorLuxottica SA Financial Statement Overview

Summary

Strong multi-year revenue growth and solid profitability, but 2025 margins softened versus prior years. Balance sheet remains sound, though leverage rose meaningfully in 2025. Cash flows are positive and improving in absolute terms, but cash conversion versus earnings is only moderate and free cash flow growth is somewhat volatile.

Income Statement

Revenue has expanded materially from 2020 to 2025, with strong step-ups in 2021–2022 and continued growth thereafter. Profitability is solid for the industry, with 2025 gross margin around 61% and net margin around 8%, though margins have eased modestly versus 2022–2024 levels (EBIT and EBITDA margins down year-over-year). Net income remains healthy but slightly lower than 2024, indicating some recent cost or mix pressure despite higher sales.

Balance Sheet

The balance sheet is generally stable with sizable equity relative to the business and moderate leverage overall. However, debt increased meaningfully in 2025 (debt-to-equity rising to ~0.44 from ~0.33 in 2024), which reduces financial flexibility and increases sensitivity to rates. Equity remains strong in absolute terms, but the upward debt trajectory in the most recent year is a key watch item.

Cash Flow

Cash generation is consistently positive, with 2025 operating cash flow of ~$5.1B and free cash flow of ~$3.6B, both higher than prior years. That said, cash conversion is only moderate: free cash flow is ~71% of net income in 2025, and operating cash flow relative to net income is below 1x across the period provided, suggesting working-capital or other cash timing headwinds. Free cash flow growth is volatile year-to-year, even though the overall level is resilient.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	27.37B	26.51B	25.39B	24.49B	19.82B
Gross Profit	16.57B	16.81B	16.05B	15.59B	12.28B
EBITDA	6.22B	6.55B	6.18B	6.10B	4.63B
Net Income	2.22B	2.36B	2.29B	2.15B	1.45B
Balance Sheet
Total Assets	63.87B	64.26B	60.52B	60.56B	59.41B
Cash, Cash Equivalents and Short-Term Investments	3.54B	2.25B	2.56B	1.96B	3.29B
Total Debt	17.04B	13.22B	11.66B	12.20B	13.02B
Total Liabilities	24.39B	23.26B	21.63B	22.41B	23.54B
Stockholders Equity	38.87B	40.38B	38.24B	37.45B	35.06B
Cash Flow
Free Cash Flow	3.62B	3.35B	3.33B	3.21B	3.52B
Operating Cash Flow	5.08B	4.87B	4.86B	4.78B	4.54B
Investing Cash Flow	-2.53B	-3.62B	-1.72B	-2.62B	-8.06B
Financing Cash Flow	-932.68M	-1.65B	-2.42B	-3.58B	-2.04B

EssilorLuxottica SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 159.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESLOY, the sentiment is Negative. The current price of 159.07 is above the 20-day moving average (MA) of 142.33, above the 50-day MA of 151.47, and above the 200-day MA of 156.15, indicating a bearish trend. The MACD of -6.99 indicates Positive momentum. The RSI at 30.24 is Neutral, neither overbought nor oversold. The STOCH value of 6.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ESLOY.

EssilorLuxottica SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ESLOY	67 Neutral	$115.20B	55.67	6.01%	1.41%	6.06%	3.53%
WRBY	60 Neutral	$3.36B	-112.73	0.46%	―	14.55%	―
BLCO	60 Neutral	$6.37B	-16.79	-4.69%	―	6.23%	17.53%
XRAY	52 Neutral	$2.66B	-3.81	-36.45%	5.61%	-7.08%	-113.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%